Key Highlights

• Pacira BioSciences (NASDAQ: PCRX) will transfer its iovera° cryoanalgesia business to Zimmer Biomet for up to $140.0 million.

• The agreement consists of an upfront payment of $70.0 million and additional contingent consideration of up to $70.0 million.

• About 8% of Pacira’s employees, or 66 staff members, will join Zimmer Biomet following the transaction.

• Contingent payments may reach $18.5 million, $23.5 million, or $28.0 million if specified revenue thresholds are achieved.

Deal Terms Unveiled

Pacira BioSciences (NASDAQ: PCRX) has reached an agreement to divest its iovera° cryoanalgesia business to Zimmer Biomet in a structured transaction. The arrangement reflects Pacira’s strategic decision to concentrate on its remaining therapeutic assets. Zimmer Biomet will assume ownership through its subsidiary, Zimmer, Inc.

Financial Structure of the Agreement

The transaction is built around an initial cash payment of $70.0 million, which may be adjusted based on standard working capital considerations. Beyond this, Pacira stands to receive further payments contingent on the commercial performance of the iovera° product line. These additional payments are tied to revenue benchmarks that must be met by the end of 2031.

Performance-Based Milestones

The contingent payments are structured around annual revenue targets. If net sales of iovera° reach or surpass $50.0 million in any given year between 2027 and 2031, Pacira will be eligible for a payment of $18.5 million. Should sales meet or exceed $60.0 million in a calendar year, the payment increases to $23.5 million.

The highest tier, triggered by sales reaching or exceeding $70.0 million, would result in a payment of $28.0 million. Each milestone is assessed independently for each applicable period.

Employee Transition

Following the completion of the transaction, roughly 8% of Pacira’s workforce, approximately 66 employees, will transition to Zimmer Biomet. This move underscores Zimmer’s intent to maintain operational continuity while integrating the iovera° business. Pacira will retain its remaining staff and continue developing its core therapeutic programs.

Regulatory and Closing Requirements

The transaction is anticipated to finalize once all customary regulatory and closing conditions are satisfied. Both companies have agreed to standard contractual protections, including representations, warranties, and indemnification terms. Pacira will also comply with post-closing obligations, such as non-compete and confidentiality provisions.

Strategic Implications

For Pacira, the divestiture enables a sharper focus on its remaining pipeline, particularly its spasticity treatment programs. Zimmer Biomet, meanwhile, gains a product line that complements its existing pain management offerings. The acquisition aligns with Zimmer’s broader efforts to expand its portfolio of non-opioid pain solutions, addressing growing demand in the orthopedic and surgical markets.

Financial and Operational Outlook

Pacira plans to allocate the upfront proceeds toward strengthening its financial position and advancing its core therapeutic initiatives. The potential for additional payments based on iovera°’s performance under Zimmer’s stewardship provides further upside. Market observers will closely track the product’s commercial success as a determinant of future milestone payments, which could influence Pacira’s financial trajectory in the coming years.

 

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.